The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.
The James P. Allison Institute at The University of Texas MD Anderson Cancer Center hosted its second annual scientific symposium on Oct. 10. The symposium, with more than 900 attendees, featured two Nobel laureates and a $5 million gift from the David and Eula Wintermann Foundation to advance the work of the Allison Institute.
Researchers from The University of Texas MD Anderson Cancer Center have demonstrated that patients with metastatic non-squamous non-small cell lung cancer (NSCLC) harboring specific mutations in the STK11 and/or KEAP1 tumor suppressor genes were more likely to benefit from adding the immunotherapy tremelimumab to a combination of durvalumab plus chemotherapy to overcome treatment resistance typically seen in this patient population.
The University of Texas MD Anderson Cancer Center today announced an agreement to become a Women’s Cancer Partner with the Union for International Cancer Control (UICC), marking a significant collaboration to improve breast and cervical cancer care worldwide.
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.
This special edition features advances in radiation therapy approaches presented by MD Anderson researchers at the 2024 American Society for Radiation Oncology (ASTRO) Annual Meeting. Information on all MD Anderson ASTRO Annual Meeting content can be found at MDAnderson.org/ASTRO.
The University of Texas MD Anderson Cancer Center today announced its first-ever academic journal, Advances in Cancer Education & Quality Improvement (ACE-QI). The journal will publish research, training program summaries and quality improvement interventions for the oncology provider community.
The University of Texas MD Anderson Cancer Center has posthumously awarded Michael Frumovitz, M.D., with the Julie and Ben Rogers Award for Excellence in Patient Care. The annual award recognizes employees who consistently demonstrate excellence in their work and dedication to MD Anderson’s mission to end cancer.
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.
According to researchers at The University of Texas MD Anderson Cancer Center, 80% of patients with previously untreated or relapsed/refractory advanced-phase chronic myeloid leukemia (CML) – including both accelerated or myeloid blast phases of the disease – or Philadelphia chromosome-positive acute myeloid leukemia (AML) achieved a bone marrow remission when treated with a novel combination of decitabine, venetoclax and ponatinib.
Treatment with a combination of haloperidol and lorazepam reduced symptoms of agitated delirium, a common end-of-life condition for patients with advanced cancers, compared with haloperidol alone, according to a new study led by researchers at The University of Texas MD Anderson Cancer Center.
The antibody-drug conjugate (ADC) puxitatug samrotecan (AZD8205) demonstrated a manageable safety profile consistent with similar ADCs and initial efficacy in heavily pretreated patients with advanced or metastatic solid tumors, according to interim data shared today at the 2024 European Society for Medical Oncology (ESMO) Congress by researchers from The University of Texas MD Anderson Cancer Center.
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer research from MD Anderson experts.
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer research from MD Anderson experts. This special edition features compelling data on lung cancer advances presented by MD Anderson researchers at the 2024 World Conference on Lung Cancer.
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.
Tens of millions of Americans are being exposed to tobacco content on streaming services, according to new research from The University of Texas MD Anderson Cancer Center.
The University of Texas MD Anderson Cancer Center today was awarded nine grants totaling over $21.4 million from the Cancer Prevention and Research Institute of Texas (CPRIT) in support of two new core facilities, faculty recruitment and groundbreaking cancer research across all areas of the institution.
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.
Natural killer (NK) cells engineered to express interleukin-21 (IL-21) demonstrated sustained antitumor activity against glioblastoma stem cell-like cells (GSCs) both in vitro and in vivo, according to new research from The University of Texas MD Anderson Cancer Center.
The University of Texas MD Anderson Cancer Center last night recognized over 100 faculty members at its annual Celebration of Faculty Excellence awards ceremony, acknowledging their compassionate care, exceptional contributions to their fields and the distinction they have brought to the institution.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right